Article and Video CATEGORIES

Cancer Journey

Search By

 

Dr. Aakash Desai, MBBS, MPH serves as an Assistant Professor of Medicine at the O'Neal Cancer Center, University of Alabama Birmingham. His pioneering research is primarily concentrated in the realm of evidence-based oncology, clinical trials, drug development, healthcare delivery, and quality of cancer care. He holds a particular interest in Thoracic Oncology and drug development.

Click here for more information about Dr. Desai. 

 

Leading Developments and Current Questions in Lung Cancer Panel Discussions
AlexandraGBeneke
Drs. Desai and Abu Rous discuss emerging information and trial data as presented at ASCO 2024.
Author
Aakash Desai, MD, MPH - Guest Faculty
Image
Trial data ASCO 2024

In this video series from ASCO 2024, Drs. Aakash Desai and Fauwzi Abu Rous discuss trial dates and clinical data as presented at the 2024 ASCO.

To watch the complete playlist, click here. 

 

 

 

 

Video Language

Next Previous link

Previous PostNext Post

Related Content

Online Community

An antibody–drug conjugate (ADC) works a bit like a Trojan horse. It has three main components:

  1. The antibody, which serves as the “horse,” specifically targets a protein found on cancer...

Bispecifics, or bispecific antibodies, are advanced immunotherapy drugs engineered to have two binding sites, allowing them to latch onto two different targets simultaneously, like a cancer cell and a T-cell, effectively...

The prefix “oligo–” means few. Oligometastatic (at diagnosis) Oligoprogression (during treatment)

There will be a discussion, “Studies in Oligometastatic NSCLC: Current Data and Definitions,” which will focus on what we...

Radiation therapy is primarily a localized treatment, meaning it precisely targets a specific tumor or area of the body, unlike systemic treatments (like chemotherapy) that affect the whole body.

The...

Biomarkers are genetic mutations (like EGFR, ALK, KRAS, BRAF) or protein levels (like PD-L1) in tumor cells that help guide personalized treatment, especially NSCLC, directing patients to targeted therapies or immunotherapies...

Hi Stan!  So good to hear from you.  I'm sorry for the late response.  I too have been out of town with family and missed your post, probably because I was...

It is so good to hear from you!  And I am so happy to hear that your holidays have been good and that you are doing well.  It sounds like your...

Recent Comments

JOIN THE CONVERSATION
Biomarkers
By JanineT GRACE … on
Radiation Therapy
By JanineT GRACE … on
Oligometastatic vs Oligoprogression
By JanineT GRACE … on
Hi Stan!! and happiest of holidays!
By dbrock on